D8-MMAD-Demethyldolastatin-10-D8-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemED8-MMADCat. No.: HY-15581SSynonyms: Demethyldolastatin 10 D8; Monomethylauristatin D D8;Monomethyl Dolastatin 10 D8分式: CHDNOS分量: 779.11作靶点: ADC Cytotoxin; Microtubule/Tubulin作通路: Antibody-drug Conjugate/ADC Related; Cell Cycle/D

2、NADamage; Cytoskeleton储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (128.35 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.2835 mL 6.4176 mL 12.8352 mL5 mM 0.2567 mL 1.2835 mL 2.5670 mL10 mM 0.1284 mL

3、 0.6418 mL 1.2835 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 D8-MMADMMAD的氘代形式。IC50 & Target IC50 & Target: Tubulin 1体外研究MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE

4、homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of 2.0. The resulting conjugatesdemonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells.When compared with ADCs prepared by cysteine alkylation following native interchain disu

5、lfide reduction,site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity 1.体内研究 The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. Theyalso have an improved toxicology profile in rats 1.REFERENCES1. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792